C19 Notes

Recent Posts

Recent Posts

Pages: 1 2 3 4 5 ... 10
21
C19 Notes Database / Re: mRNA vaccine stability
« Last post by stog on March 14, 2021, 12:57:43 PM »
a new safety review of 10 million patients who received the vaccine uncovered

"no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or in any particular country.

"In fact, the observed number of these types of events are significantly lower in those vaccinated than what would be expected among the general population,"



https://www.cbc.ca/news/world/coronavirus-covid19-canada-world-march11-2021-1.5945218
22
C19 Notes Database / Re: mRNA vaccine stability
« Last post by stog on March 14, 2021, 12:36:29 PM »
also

Quote
"
At the time of this report, nearly 125,000 people across the UK have died within 28 days of a positive test for coronavirus (COVID-19). Rates of COVID-19 infection and hospitalisation remain high.Vaccination is the single most effective way to reduce deaths and severe illness from COVID-19. A national immunisation campaign has been underway since early December 2020.Two COVID-19 vaccines, Pfizer/BioNTech and Oxford University/AstraZeneca vaccines, are currently being used in the UK. Both have been authorised for supply by the Medicines and Healthcare products Regulatory Agency (MHRA) following a thorough review of safety, quality and efficacy information from clinical trials. In clinical trials, both vaccines showed very high levels of protection against symptomatic infections with COVID-19. We expect data to be available soon on the impact of the vaccination campaign in reducing infections and illness in the UK.All vaccines and medicines have some side effects. These side effects need to be continuously balanced against the expected benefits in preventing illness.

As of 28 February 2021, for the UK, 33,207 Yellow Cards have been reported for the Pfizer/BioNTech, 54,180 have been reported for the Oxford University/AstraZeneca vaccine, and 251 have been reported where the brand of the vaccine was not specified.
For both vaccines the overall reporting rate is around 3 to 6 Yellow Cards per 1,000 doses administered.

In the week since the previous summary for 21 February 2021 we have received a further 3,492 Yellow Cards for the Pfizer/BioNTech vaccine, 11,263 for the Oxford University/AstraZeneca vaccine and 74 where the brand was not specified. A higher number of doses of the Oxford University/AstraZeneca vaccine were administered in the last week than the Pfizer/BioNTech vaccine.


It is important to note that Yellow Card data cannot be used to derive side effect rates or compare the safety profile of COVID-19 vaccinations as many factors can influence ADR reporting.


For both vaccines, the overwhelming majority of reports relate to injection-site reactions (sore arm for example) and generalised symptoms such as ‘flu-like’ illness, headache, chills, fatigue (tiredness), nausea (feeling sick), fever, dizziness, weakness, aching muscles, and rapid heartbeat. Generally, these happen shortly after the vaccination and are not associated with more serious or lasting illness.
These types of reactions reflect the normal immune response triggered by the body to the vaccines. They are typically seen with most types of vaccine and tend to resolve within a day or two. The nature of reported suspected side effects is broadly similar across age groups, although, as was seen in clinical trials and as is usually seen with other vaccines, they may be reported more frequently in younger adults.

Severe allergy
On 9 December 2020, the MHRA issued preliminary guidance on severe allergic reactions after the Pfizer/BioNTech vaccine due to early reports of anaphylaxis. Following further detailed review, this advice was amended on 30 December to the current advice. This advice is that people with a previous history of severe allergic reactions to any ingredients of the vaccine should not receive it. People who receive the vaccine should be monitored for at least 15 minutes afterwards.

Widespread use of the vaccine now suggests that severe allergic reactions to the Pfizer/BioNTech vaccine are very rare. Anaphylaxis can also be a very rare side effect associated with most other vaccines.


Following very substantial exposure across the UK population, no other new safety concerns have been identified from reports received so far.


Conclusion


The increases in number of ADR reports reflects the increase in vaccine deployment as new vaccination centres have opened across the UK
The number and nature of suspected adverse reactions reported so far are not unusual in comparison to other types of routinely used vaccines    The overall safety experience with both vaccines is so far as expected from the clinical trials Based on current experience, the expected benefits of both COVID-19 vaccines in preventing COVID-19 and its serious complications far outweigh any known side effects   

As with all vaccines and medicines, the safety of COVID-19 vaccines is being continuously monitored

https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
23
C19 Notes Database / Re: mRNA vaccine stability
« Last post by stog on March 14, 2021, 12:26:23 PM »
Comment on above

remember we are all different, age , gender, medical condition and history and many of us even physiologically/biochemically and for example , the birth control pill also causes blood clots and a million more side affects yet it is often used for many menstrual cycle complaints.

also


24
C19 Notes Database / Re: mRNA vaccine stability
« Last post by stog on March 14, 2021, 12:10:58 PM »
also released today  is the latest on the Oxford AZ vaccine from the Norwegian Medicines Agency on the 4 cases of blood clots so far reported there.

they recommend those who feel increasingly unwell with several large blue patches (skin haemorrhages) more than three days after vaccination, to consult the out-of-hours medical service or their doctor as soon as possible.


Similar incidents have been reported in other European countries, and the European Medicines Agency (EMA) is considering whether there may be an association with the coronavirus vaccines. So far, no conclusion has been reached.


Common to these patients is that they have had a reduced number of blood platelets. Blood clots and subsequent brain haemorrhages are a rare condition.

https://www.fhi.no/en/news/2021/norwegian-medicines-agency-notified-of-blood-clots-and-bleeding-in-younger-/
25
C19 Notes Database / mRNA vaccine stability
« Last post by stog on March 14, 2021, 11:29:45 AM »

Hacked EMA emails and mRNA vaccine stability

This week a piece in the British Medical Journal provides some insight into how the medical regulatory bodies scrutinised the novel RNA vaccines that were the science marvels of 2020.

Investigative journalist Serena Tinari was one of the people who received anonymously a large, though selective, bundle of hacked emails and documents dating back to November copied from the servers of the European Medicines Agency.

They make mention of concerns the Agency had over the levels of effective RNA contained in some batches of the industrially produced Pfizer Biontech Covid vaccine compared to the laboratory produced doses.

The EMA did subsequently licence the vaccine - the problem having presumably been solved. However, as Serena describes, she was then surprised that the companies and agencies she and the BMJ approached would not tell her what the threshold was for adjudging acceptable levels, given as is well known, the fragility of mRNA and the need to store it carefully.

They said it was commercially sensitive. But as RNA researcher Prof Anna Blakney tells Science in Action, there are fascinating reasons why that might simply not be known, and also why precise accuracy likely doesn’t matter too much compared to the better-known clinical efficacy these vaccines continue to demonstrate.

2nd item in this episode - programme available for 28 days from post date
https://www.bbc.co.uk/programmes/w3cszky4

===

the BMJ Article is here -- March 10 2021 https://www.bmj.com/content/372/bmj.n627
26
C19 Notes Database / Re: A reminder why we have restrictions and wear a mask
« Last post by stog on February 09, 2021, 05:59:33 PM »
The Parliamentary Office of Science and Technology puts out regular briefings, which are clear, succinct, comprehensive overviews of a particular area.


the latest COVID-19 analysis, as evidence becomes available


https://post.parliament.uk/tag/covid-19/

==

articles include


COVID-19 vaccine roll-out started in the UK on 8 December 2020. Results from Phase 3 clinical trials have been published for all the vaccines approved for use in the UK. But how does the performance of vaccines under real world conditions differ from clinical trial results? When will we able to observe the impacts of the COVID-19 vaccination programme?

 https://post.parliament.uk/the-performance-of-covid-19-vaccines-in-clinical-trials-and-in-real-world-conditions/


The Government’s COVID-19 Winter Plan, relies on three things to provide the UK with a “route back to normality”: vaccines, treatments and testing. In addition to laboratory-based tests, lateral flow tests are being used for rapid testing in communities and workplaces. What are the latest data on how good these tests are? What are the pros and cons of using them for mass testing?

https://post.parliament.uk/mass-testing-for-covid-19-january-update-on-lateral-flow-tests/

In recent months several new variants of the SARS-CoV-2 virus have been detected in various countries around the world. This article examines how these variants arise, how genetic variation might affect the characteristics of the virus, and the possible impact that these new variants might have on the course of the pandemic.https://post.parliament.uk/sars-cov-2-virus-variants-a-year-into-the-covid-19-pandemic/

The rapid production of safe, effective and consistent vaccines is essential for supporting COVID-19 immunisation programmes in the UK and globally. However, manufacturing vaccines is challenging for various reasons that include the complex processes involved, the specialist knowledge and experience required, and the natural variability of the biological materials and systems used. Urgent demand is leading to manufacturers and governments taking on significant financial risks in order to speed up production. What is the UK Government doing to accelerate vaccine manufacture? How are vaccines made? Why is manufacturing vaccines at large scales so challenging?

https://post.parliament.uk/manufacturing-covid-19-vaccines/
27
C19 Notes Database / Re: A reminder why we have restrictions and wear a mask
« Last post by stog on February 02, 2021, 04:02:34 PM »
then this
28
C19 Notes Database / Re: A reminder why we have restrictions and wear a mask
« Last post by stog on January 31, 2021, 10:46:08 AM »
Reality as endured in this Opinion piece by a NHS consultant anaesthetist.

Quote
I'm an NHS consultant anaesthetist. I see the terror in my Covid patients' eyes
As a hospital consultant working in intensive care, the reality of coronavirus and patients’ fear is brought home to me every day

https://www.theguardian.com/world/2021/jan/31/im-an-nhs-consultant-anaesthetist-i-see-the-terror-in-my-covid-patients-eyes
29
C19 Notes Database / Re: A reminder why we have restrictions and wear a mask
« Last post by stog on January 20, 2021, 03:05:36 PM »
Herewith a website set up to answer the Anti-Virus: misinformation The Covid-19 FAQ

Quote

Q. Who paid for this?

A. Nobody. We've been writing this site in our spare time. We haven't requested or received any money whatsoever and we've paid for the website costs out of our own pockets. Some of us have been paid to write articles on Covid for various news and comment outlets, but we've received no money for this website. (Update: Notion, the service we've used to build this site, has given us a free plan as part of its efforts to support grassroots groups fighting Covid. We are extremely grateful to them.)


Q. Why should I listen to you?

A. All of our arguments link to credible, peer-reviewed literature where relevant. Don't take our word for anything – follow the links, read the evidence cited on both sides, and decide for yourself.

Q. Surely you don't think there's just one "right answer" to questions on COVID. It's a new disease, after all. How can you be sure you're not just as wrong as the Sceptics?
A. We do not claim to have a single right answer, and we change our minds as the evidence changes. But there are some clearly wrong answers that persist because people are unaware of new evidence, or unwilling to change their minds. This site is about highlighting those persistent wrong answers.


Q. Why are you singling out specific individuals? Do you have some kind of grudge against them?

A. A few people, for whatever reason, have consistently made false claims and bad predictions throughout the COVID pandemic, and have refused to admit when they've got it wrong. Some of these people have been very prominent and influential during the pandemic. We try to use their own words to show that many of them are not reliable people to listen to.



https://www.covidfaq.co/
30
C19 Notes Database / Re: Contact Tracing
« Last post by stog on January 19, 2021, 02:51:16 PM »
The UK NHS  Test and Trace provides training for suitable candidates who wish to work in contact tracing and there is also the Johns Hopkins contact tracing course, which is recommended to people who haven't previously done contact tracing. It goes into the underlying principles and obviously you'd have to be mindful of administrative differences from the UK system, but it is worth going through if you are interested in the subject.

 link is to an official university-accredited and widely recommended course, used by contact tracers across the USA and elsewhere

https://www.coursera.org/learn/covid-19-contact-tracing

Pages: 1 2 3 4 5 ... 10